AAPS PharmSci 360 2026 五大要点:可审计AI、口服肽与抗体成本
AAPS PharmSci 360 2026: 5 Takeaways on AI, Oral Peptides, and Antibody Costs
AAPS PharmSci 360 2026于10月25日至28日在新奥尔良举行,聚焦可审计AI、建模指导的制剂开发、口服肽递送、高浓度抗体混悬液及单抗成本降至每克10美元。Nanoform公布440 mg/mL曲妥珠单抗混悬液18个月稳定性数据;IIT Delhi的Anurag Rathore介绍其团队在不削减纯化步骤的情况下降低单抗成本。
News|Articles|November 2, 2026
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
AAPS PharmSci 360 2026 brought pharmaceutical scientists to the Ernest N. Morial Convention Center in New Orleans from October 25 to 28, and the program kept returning to one question: how to make drug development smarter, not just faster. Julie Gerberding, MD, MPH, president and chief executive officer of the Foundation for the National Institutes of Health (FNIH), opened the meeting on October 25 with a plenary titled "Adaptive Intelligence: Accelerating Biomedical Innovation," which covered artificial intelligence (AI), adaptive clinical trials, and novel alternative methods for drug development.¹ Below are five takeaways from BioPharm International®'s coverage of the meeting, which are also featured in our video recap.
Related to this article
October 30th, 2026
In an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 440 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
October 29th, 2026
In the final part of a three-part interview, Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team has cut monoclonal antibody costs toward $10 per gram and why process intensification will spread one unit operation at a time.
October 29th, 2026
As part of BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall explains why stability and viscosity have kept antibody formulations below 200 mg/mL, and how a low-temperature particle engineering process and non-aqueous suspensions could support ultra-high concentrations.
October 28th, 2026
Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team cuts monoclonal antibody costs without cutting purification steps, and why the $10-per-gram target could make antibodies viable for infectious disease and global access.
October 27th, 2026
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
November 2nd, 2026
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
November 2nd, 2026
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
October 30th, 2026
This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
来源:BioPharm International · biopharminternational.com





